Bright Operating Income from 2010 to 2026
| DRUG Stock | USD 90.08 0.99 1.11% |
Operating Income | First Reported 2019-12-31 | Previous Quarter -5.7 M | Current Value -6.9 M | Quarterly Volatility 1.9 M |
Check Bright Minds financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bright Minds' main balance sheet or income statement drivers, such as Depreciation And Amortization of 54.2 K, Interest Expense of 49.2 K or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.73. Bright financial statements analysis is a perfect complement when working with Bright Minds Valuation or Volatility modules.
Bright | Operating Income | Build AI portfolio with Bright Stock |
The Operating Income trend for Bright Minds Biosciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bright Minds is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Bright Minds' Operating Income Growth Pattern
Below is the plot of the Operating Income of Bright Minds Biosciences over the last few years. Operating Income is the amount of profit realized from Bright Minds Biosciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Bright Minds Biosciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Bright Minds' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Bright Operating Income Regression Statistics
| Arithmetic Mean | (4,407,976) | |
| Coefficient Of Variation | (130.26) | |
| Mean Deviation | 5,067,088 | |
| Median | (236,151) | |
| Standard Deviation | 5,741,900 | |
| Sample Variance | 33T | |
| Range | 14.7M | |
| R-Value | (0.79) | |
| Mean Square Error | 13.4T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (894,204) | |
| Total Sum of Squares | 527.5T |
Bright Operating Income History
About Bright Minds Financial Statements
Bright Minds stakeholders use historical fundamental indicators, such as Bright Minds' Operating Income, to determine how well the company is positioned to perform in the future. Although Bright Minds investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bright Minds' assets and liabilities are reflected in the revenues and expenses on Bright Minds' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bright Minds Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -12.5 M | -11.9 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Bright Minds Correlation against competitors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Can Biotechnology industry sustain growth momentum? Does Bright have expansion opportunities? Factors like these will boost the valuation of Bright Minds. Projected growth potential of Bright fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bright Minds demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Bright Minds Biosciences's market price often diverges from its book value, the accounting figure shown on Bright's balance sheet. Smart investors calculate Bright Minds' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Bright Minds' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bright Minds' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bright Minds should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.